Overview
- A first-in-human CAR-T using stem-cell memory T cells, a long-lived subset, produced five complete remissions in 11 patients with tough blood cancers at far lower doses with milder side effects.
- The stem-like cells expanded and persisted without preconditioning chemotherapy, with responses reported at doses as low as 250,000 cells per kilogram.
- Rutgers researchers tied high levels of senescent CD8+ T cells in the starting material to poor lab expansion and clinical failure, and they flagged AP1, KLF5, and RUNX2 as key regulators of this state.
- A review of registered studies reports a rapid move toward multifunctional CAR-T designs, now about one-third of trials, alongside a sharp rise in autoimmune disease programs.
- Safety and scalability remain the chokepoints as teams test drugs to blunt cytokine-release syndrome and refine receptor designs, underscoring the need for standardized manufacturing and longer follow-up.